Delayed
OTC Markets
13:26:13 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
0.0001
USD
|
0.00%
|
|
0.00%
|
+9,900.00%
|
Fiscal Period: September |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
9.209
|
6.001
|
2.916
|
1.842
|
3.07
|
0.4911
|
Enterprise Value (EV)
1 |
9.425
|
6.35
|
3.365
|
2.416
|
3.668
|
1.119
|
P/E ratio
|
-6
x
|
-9.53
x
|
-1.9
x
|
-2.92
x
|
-2
x
|
-0.71
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
186
x
|
83.6
x
|
18
x
|
-252
x
|
12
x
|
5.28
x
|
FCF Yield
|
0.54%
|
1.2%
|
5.54%
|
-0.4%
|
8.31%
|
18.9%
|
Price to Book
|
-3.77
x
|
-2
x
|
-0.78
x
|
-0.43
x
|
-0.59
x
|
-0.09
x
|
Nbr of stocks (in thousands)
|
153,483
|
153,483
|
153,483
|
153,483
|
153,483
|
153,483
|
Reference price
2 |
0.0600
|
0.0391
|
0.0190
|
0.0120
|
0.0200
|
0.003200
|
Announcement Date
|
18-01-16
|
19-01-15
|
20-01-14
|
21-01-13
|
22-01-13
|
23-01-13
|
Fiscal Period: September |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.9611
|
-0.5403
|
-0.7366
|
-0.6637
|
-0.8424
|
-0.6012
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-0.9739
|
-0.5591
|
-0.7585
|
-0.5596
|
-0.8771
|
-0.6393
|
Net income
1 |
-0.9739
|
-0.5591
|
-0.7585
|
-0.5596
|
-0.8771
|
-0.6393
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0100
|
-0.004103
|
-0.0100
|
-0.004108
|
-0.0100
|
-0.004510
|
Free Cash Flow
1 |
0.0506
|
0.0759
|
0.1865
|
-0.009582
|
0.3048
|
0.2117
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18-01-16
|
19-01-15
|
20-01-14
|
21-01-13
|
22-01-13
|
23-01-13
|
Fiscal Period: September |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
0.22
|
0.35
|
0.45
|
0.57
|
0.6
|
0.63
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
0.05
|
0.08
|
0.19
|
-0.01
|
0.3
|
0.21
|
ROE (net income / shareholders' equity)
|
49.8%
|
20.5%
|
22.5%
|
14%
|
18.6%
|
12.1%
|
ROA (Net income/ Total Assets)
|
-268%
|
-468%
|
-1,491%
|
-8,774%
|
-12,034%
|
-3,738%
|
Assets
1 |
0.3629
|
0.1194
|
0.0509
|
0.006378
|
0.007289
|
0.0171
|
Book Value Per Share
2 |
-0.0200
|
-0.0200
|
-0.0200
|
-0.0300
|
-0.0300
|
-0.0400
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18-01-16
|
19-01-15
|
20-01-14
|
21-01-13
|
22-01-13
|
23-01-13
|
|
1st Jan change
|
Capi.
|
---|
| +9,900.00% | 15.35K | | +7.75% | 113B | | +10.36% | 106B | | +0.41% | 22.27B | | -11.97% | 22.22B | | -5.99% | 19.43B | | -37.36% | 17.87B | | -5.39% | 17.24B | | +7.02% | 14.29B | | +36.26% | 12.52B |
Bio Therapeutic Drugs
|